Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
We utilise our cutting-edge, exclusive workflow to develop focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology leverages molecular simulations to examine a vast array of proteins, capturing their dynamics in both isolated forms and in complexes with other proteins. Through ensemble virtual screening, we thoroughly account for the protein's conformational mobility, identifying critical binding sites within functional regions and distant allosteric locations. This detailed exploration ensures that we comprehensively assess every possible mechanism of action, with the objective of identifying novel therapeutic targets and lead compounds that span a wide spectrum of biological functions.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
Q86YR7
UPID:
MF2L2_HUMAN
Alternative names:
Dbs-related Rho family guanine nucleotide exchange factor; MCF2-transforming sequence-like protein 2
Alternative UPACC:
Q86YR7; O94942; Q6P2B8; Q6ZVJ5; Q8N318
Background:
The Probable guanine nucleotide exchange factor MCF2L2, also known as Dbs-related Rho family guanine nucleotide exchange factor and MCF2-transforming sequence-like protein 2, plays a pivotal role in cellular processes. Its primary function is likely as a guanine nucleotide exchange factor, crucial for intracellular signaling pathways.
Therapeutic significance:
Given its involvement in Type 2 diabetes mellitus, a disorder marked by insulin resistance and metabolic syndrome, MCF2L2 presents a promising target for therapeutic intervention. Understanding the role of MCF2L2 could open doors to potential therapeutic strategies aimed at mitigating the disease's progression and its associated complications.